4D Molecular Therapeutics
FDMT
134 hedge funds and large institutions have $346M invested in 4D Molecular Therapeutics in 2025 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 31 increasing their positions, 48 reducing their positions, and 19 closing their positions.
487% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $191K
129% more capital invested
Capital invested by funds: $151M → $346M (+$195M)
74% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 19
12% more funds holding
Funds holding: 120 → 134 (+14)
2.52% less ownership
Funds ownership: 87.21% → 84.68% (-2.5%)
35% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.76M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.89M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.2M |
| 4 |
Renaissance Technologies
New York
|
+$1.18M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.24M |
| 2 |
Millennium Management
New York
|
-$2M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.65M |
| 4 |
Two Sigma Investments
New York
|
-$1.54M |
| 5 |
Two Sigma Advisers
New York
|
-$1.16M |
FDMT Hedge Fund Activity: Q3 2025 in Review
134 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q3 2025, worth a combined $346M — up 129% from $151M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new FDMT positions and 19 closed out — a net gain of 14 holders — while 31 added to existing stakes and 48 trimmed.
The largest buyer was Armistice Capital, adding an estimated $4.76M. The largest seller was JP Morgan Chase, cutting an estimated $2.24M.
- 134 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q3 2025, up from 120 in Q2 2025.
- Funds reported $346M of 4D Molecular Therapeutics stock for Q3 2025, up 129% quarter-over-quarter.
- 33 funds opened new 4D Molecular Therapeutics positions in Q3 2025 and 19 closed out, a net change of +14 holders.
- The largest 4D Molecular Therapeutics buyer in Q3 2025 was Armistice Capital, an estimated $4.76M added.
- The largest 4D Molecular Therapeutics seller in Q3 2025 was JP Morgan Chase, an estimated $2.24M sold.
Based on aggregated 13F filings for Q3 2025.